Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEXATE-AQ vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, which is required for the synthesis of purines and pyrimidines. This leads to inhibition of DNA, RNA, and protein synthesis, particularly in rapidly dividing cells. It also has immunosuppressive effects via inhibition of T cell activation and reduction of inflammatory cytokines.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
FDA-approved: Chemotherapy for gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole, acute lymphocytic leukemia, meningeal leukemia, breast cancer, head and neck cancer, cutaneous T-cell lymphoma, lung cancer, non-Hodgkin's lymphoma, osteosarcoma, and mycosis fungoides.,FDA-approved: Severe, active rheumatoid arthritis (RA) in adults who have failed first-line therapy.,FDA-approved: Pediatric patients with polyarticular juvenile idiopathic arthritis (p JIA) who have failed first-line therapy.,FDA-approved: Psoriasis (severe, recalcitrant) in adults.,Off-label: Prevention of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation.,Off-label: Crohn's disease (maintenance of remission in steroid-dependent patients).,Off-label: Ectopic pregnancy (medical management).
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
Methotrexate: 7.5-25 mg orally once weekly for rheumatoid arthritis; 30-40 mg/m2 IV weekly for mycosis fungoides; 50-75 mg/m2 IV over 4-6 hours weekly for osteosarcoma; 15-20 mg/m2 IM weekly for psoriasis.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life is approximately 3–10 hours for low doses (<30 mg/m²) and 8–15 hours for high doses (>80 mg/m²). Prolonged to 48–72 hours in patients with third-space effusions or renal impairment.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Metabolized primarily in the liver to polyglutamates (which are active metabolites) via folylpolyglutamate synthetase. Partial metabolism via aldehyde oxidase and xanthine oxidase to 7-hydroxymethotrexate. Methotrexate is also partially metabolized by intestinal flora. Elimination is primarily renal via glomerular filtration and active tubular secretion.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Renal excretion predominates (80-90% as unchanged drug) via glomerular filtration and active tubular secretion. Biliary/fecal elimination is minor (<10%).
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Approximately 50–60% bound primarily to albumin. Weakly bound and readily displaceable by other drugs.
Approximately 85-90% bound to serum albumin.
Vd: 0.4–0.8 L/kg (initial 0.18 L/kg, steady-state 0.4–0.8 L/kg). Distributes into third-space fluids (pleural, ascitic), leading to prolonged elimination.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral: 30–60% (dose-dependent; saturable absorption at high doses). Intramuscular: 80–100%. Subcutaneous: approximately 90%.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
For GFR 40-59 m L/min: reduce dose by 20%; GFR 20-39 m L/min: reduce dose by 40%; GFR <20 m L/min: contraindicated.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
For acute lymphoblastic leukemia (ALL): 15-20 mg/m2 IM once weekly as maintenance; for osteosarcoma: 12 g/m2 IV over 4 hours with leucovorin rescue.
Not established; safety and efficacy not determined in pediatric patients.
Start at lowest recommended dose (e.g., 5 mg orally once weekly) with careful monitoring for renal function, hepatic function, and folate levels; adjust based on tolerance.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
Boxed Warning: Methotrexate can cause fetal death or teratogenic effects when administered to pregnant women. It is contraindicated in pregnant women with psoriasis or RA. It also has a boxed warning for severe toxicity and death due to inadvertent daily (as opposed to weekly) dosing; hepatic toxicity, including acute hepatitis and chronic hepatic fibrosis; myelosuppression, including severe bone marrow suppression; and pulmonary toxicity, including acute or chronic interstitial pneumonitis. Additionally, anaphylactic reactions can occur. For patients with psoriasis, methotrexate should be used only for severe, recalcitrant cases unresponsive to other therapy.
None.
Fatal toxicities (including hematologic, hepatic, pulmonary, renal, dermatologic, and GI) can occur with methotrexate; monitor closely.,Hepatic toxicity: Monitor liver function tests; avoid or use with caution in patients with active liver disease or alcohol abuse.,Pulmonary toxicity: Acute or chronic interstitial pneumonitis may occur; monitor for cough, fever, dyspnea, and hypoxia.,Myelosuppression: Monitor CBC and platelet counts regularly; severe pancytopenia can occur.,Renal toxicity: Adequate renal function is essential; avoid NSAIDs, salicylates, and other nephrotoxic drugs if possible.,Gastrointestinal toxicity: Mucositis, ulcerative stomatitis, diarrhea, and hemorrhagic enteritis may occur.,Dermatologic toxicity: Phototoxicity, radiation recall, and severe skin reactions (including Stevens-Johnson syndrome) can occur.,Immunosuppression: Increased risk of infections, including opportunistic infections; avoid live vaccines.,Carcinogenicity: Increased risk of lymphoproliferative disorders (may be reversible with discontinuation).,Concomitant use with proton pump inhibitors (PPIs) may increase methotrexate levels.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to methotrexate or any component of the formulation.,Pregnancy and breastfeeding (due to risk of fetal death/teratogenicity and excretion in breast milk).,Patients with psoriasis or RA who have alcoholism, alcoholic liver disease, chronic liver disease, or overt immunodeficiency.,Pre-existing blood dyscrasias (severe anemia, leukopenia, neutropenia, thrombocytopenia).,Concomitant use with live vaccines.
Hypersensitivity to AURLUMYN or any of its components.
Avoid folic acid-rich foods (leafy greens, fortified grains) in large amounts during methotrexate therapy as they may reduce efficacy. No specific food-drug interactions; maintain a well-balanced diet.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
FDA Pregnancy Category X. First trimester: High risk of miscarriage, CNS defects, craniofacial anomalies. Second trimester: IUGR, skeletal abnormalities. Third trimester: Neonatal bone marrow suppression, immunosuppression.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Contraindicated. Methotrexate is excreted in breast milk; accumulation may occur in nursing infants due to immature renal function. M/P ratio not established; theoretical risk of serious adverse effects.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
Contraindicated in pregnancy; no dose adjustment recommended due to teratogenicity. In lactating females, discontinue breastfeeding or avoid use.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Mexate-AQ (methotrexate) requires folic acid supplementation to reduce gastrointestinal and hematologic toxicity. Administer leucovorin rescue after high-dose therapy. Avoid NSAIDs, salicylates, and sulfonamides due to increased methotrexate toxicity. Monitor renal function, liver enzymes, and blood counts regularly. Contraindicated in pregnancy, breastfeeding, and active infections.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid alcohol completely while on this medication.,Report any signs of infection (fever, sore throat), unusual bleeding, or mouth ulcers immediately.,Use effective contraception during treatment and for at least 3 months after stopping.,Do not take any over-the-counter medications, especially NSAIDs (ibuprofen, naproxen), without permission.,Drink plenty of fluids to prevent kidney damage.,Attend all scheduled blood tests and appointments.,Capsules should be swallowed whole; do not crush or chew.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEXATE-AQ vs AURLUMYN, answered by our medical review team.
MEXATE-AQ is a Antineoplastic Agent that works by Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, which is required for the synthesis of purines and pyrimidines. This leads to inhibition of DNA, RNA, and protein synthesis, particularly in rapidly dividing cells. It also has immunosuppressive effects via inhibition of T cell activation and reduction of inflammatory cytokines.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEXATE-AQ and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEXATE-AQ is: Methotrexate: 7.5-25 mg orally once weekly for rheumatoid arthritis; 30-40 mg/m2 IV weekly for mycosis fungoides; 50-75 mg/m2 IV over 4-6 hours weekly for osteosarcoma; 15-20 mg/m2 IM weekly for psoriasis.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEXATE-AQ and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEXATE-AQ is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of miscarriage, CNS defects, craniofacial anomalies. Second trimester: IUGR, skeletal abnormalities. Third trimester: Neonatal . AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.